Cited by 489Autophagy in Disease and TherapyPancreatic and Hepatic Oncology ResearchCalcium signaling and nucleotide metabolism

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations

Open access
Yang, Annan, Rajeshkumar, N.V., Wang, Xiaoxu, Yabuuchi, Shinichi, Alexander, Brian M., Chu, Gerald C., Von Hoff, Daniel D., Maitra, Anirban +1 more·2014·Cancer Discovery

Published version of a preprint

Abstract

Pancreatic ductal adenocarcinoma is refractory to available therapies. We have previously shown that these tumors have elevated autophagy and that inhibition of autophagy leads to decreased tumor growth. Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of Trp53, we demonstrate that although genetic ablation of autophagy in the pancreas leads to increased tumor initiation, these premalignant lesions are impaired in their ability to progress to invasive cancer, leading to prolonged survival. In addition, mouse pancreatic cancer cell lines with differing p53 status are all sensitive to pharmacologic and genetic inhibition of autophagy. Finally, a mouse preclinical trial using cohorts of genetically characterized patient-derived xenografts treated with hydroxychloroquine showed responses across the collection of tumors. Together, our data support the critical role of autophagy in pancreatic cancer and show that inhibition of autophagy may have clinical utility in the treatment of these cancers, independent of p53 status. Significance: Recently, a mouse model with embryonic homozygous Trp53 deletion showed paradoxical effects of autophagy inhibition. We used a mouse model with Trp53 LOH (similar to human tumors), tumor cell lines, and patient-derived xenografts to show that p53 status does not affect response to autophagy inhibition. These findings have important implications on ongoing clinical trials. Cancer Discov; 4(8); 905–13. ©2014 AACR. See related commentary by Amaravadi and Debnath, p. 873 This article is highlighted in the In This Issue feature, p. 855

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0362

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autophagy is critical for cancer cell growth and tumorigenesis in mouse models of PDAC.

    “Autophagy is critical for cancer cell growth and tumorigenesis in mouse models of PDAC207–209”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [208]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yang, A., Rajeshkumar, N. V., Wang, X., Yabuuchi, S., Alexander, B. M., Chu, G. C., Von Hoff, D. D., Maitra, A., & Kimmelman, A. C.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Johns Hopkins University (US)
  • Brigham and Women's Hospital (US)
  • 4Translational Genomics Research Institute, Phoenix, Arizona; Departments of
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Kimmelman, Alec C.
Venue
Cancer Discovery
Published
2014-08-01
Volume
4
Issue
8
Pages
905-913
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2148330792
Cited by
486
References
33
Citations by year
2026: 16 · 2025: 32 · 2024: 28 · 2023: 34 · 2022: 47 · 2021: 61 · 2020: 44 · 2019: 43 · 2018: 41 · 2017: 45 · 2016: 37 · 2015: 43 · 2014: 15
FWCI
35.35
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50CA127003, R01CA157490, P30CA016672)
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
Keywords
autophagy, pancreatic ductal adenocarcinoma, p53 status, autophagy inhibition, hydroxychloroquine, KRAS-driven tumors, premalignant pancreatic lesions, tumor progression, patient-derived xenografts
MeSH terms
Animals, Autophagy, Cell Transformation, Neoplastic, Disease Models, Animal, Humans, Pancreatic Neoplasms, Tumor Suppressor Protein p53, Loss of Heterozygosity, Xenograft Model Antitumor Assays, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review